STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
The FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancer
The U.S. Food and Drug Administration has approved an oral treatment for advanced multiple myeloma, developed by Bristol Myers Squibb. This marks the first drug of its kind in a new class of medicines, called CELMoDs, which work by targeting cancer-causing proteins. The drug, sold under the brand name Zenbexus, represents a significant advancement in the treatment of blood cancer.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
